





































































Post remission consolidation by autologous HCT for AML in CR1,
negative implications for subsequent allogeneic HCT in CR2. A Study
by the Acute Leukemia Working Party of the European Society for
Blood and Marrow Transplantation (EBMT).
J.R. Passweg , M. Labopin , M. Christopeit , J. Cornelissen ,
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After autologous hematopoetic cell transplantation, (HCT in 1st complete remission (CR1), 
patients with acute myeloid leukemia (AML) may relapse and undergo allogeneic HCT in 
CR2. The aim of this study was to analyze outcome of allogeneic HCT performed in CR2 
comparing patients with prior consolidation by autologous HCT vs. patients with 
chemotherapy consolidation. Included were 2619 adults, with allogeneic HCT in CR2, in 
2000-2017 with (n=417) or without (n=2202) prior autologous HCT. Patient groups were not 
entirely comparable; patients with prior autologous HCT were younger, had less often a 
favorable cytogenetic profile, had more commonly donors other than matched siblings and 
more often received reduced intensity conditioning (RIC) conditioning. In multivariate 
analysis non relapse mortality (NRM) risks in patients with prior autologous HCT were 1.34 
(1.07-1.67), p=0.01 after adjustment for age, cytogenetic risk, transplant year, donor, 
conditioning intensity, sex matching, interval diagnosis-relapse and relapse-allogeneic HCT 
as compared to chemotherapy consolidation. Similarly, risks of events in leukemia free 
survival and graft versus host disease, relapse free survival were higher with prior autologous 
HCT, 1.17 (1.01-1.35), p=0.03 and 1.18 (1.03-1.35) p= 0.02, respectively. Risk of death was 
also higher 1.13 (0.97-1.32) p=0.1 but this was not significant. Post remission consolidation 
with autologous HCT for AML in CR1 increases toxicity of subsequent allogeneic HCT in 
CR2.  




During the past decades, autologous hematopoietic cell transplantation (HCT) has been 
widely used as consolidation treatment in patients with acute myeloid leukemia (AML) in first 
or second complete remission (CR) (1-11). Over time, donors for allogeneic stem cell 
transplantation have become available and allogeneic HCT appears to have in part replaced 
autologous HCT. 
Autologous HCT has been shown to reduce relapse rates by approximately 10% and increase 
LFS although not overall survival in a randomized clinical study (1). Consolidation by 
autologous HCT is used more commonly in patients with low and intermediate risk AML, 
while for high risk AML allogeneic HCT is more commonly recommended. Up to half of 
patients receiving consolidation by autologous HCT in CR1 will relapse and will be 
candidates for allogeneic HCT in CR2 (1). Although observational registry studies will not be 
able to answer the question whether a strategy of early allogeneic HCT is better than 
consolidation by chemotherapy or autologous HCT and allogeneic HCT in case of relapse, the 
toxicity of allogeneic HCT in CR2 in patients having received consolidation treatment by 
autologous HCT or by chemotherapy can be quantified and compared. 
This study compares mortality after allogeneic HCT in CR2 in AML patients who have 
received consolidation treatment in CR1 by autologous HCT versus those who have received 
consolidation by chemotherapy only. A difference in mortality may indicate added burden of 
toxicity by autologous HCT consolidation in case later allogeneic HCT is required to treat 
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Patients and Methods:  
This is an observational study including adult patients (≥18 years) with de novo AML (non-
APL) registered with EBMT receiving an allogeneic HCT in CR2 between the year 2000 and 
2017 and who had received either chemotherapy consolidation (n=2202) or consolidation by 
autologous HCT (n=417) in CR1. Included were patients in whom the date of relapse was 
reported and whose donor was either a matched sibling, an unrelated donor or a haploidentical 
donor. 
The EBMT is a non-profit scientific society representing more than 600 transplant centers, 
mostly located in Europe, that are required to report all consecutive stem cell transplantations 
and follow-up data once a year. Data are entered, managed and maintained in a central 
database with internet access; each EBMT center is represented in this database. Audits are 
routinely performed to determine the accuracy of the data. Patients or their legal guardians 
provide informed consent authorizing the use of their personal information for research 
purposes according to the declaration of Helsinki. The Review Board of the EBMT approved 
this study. 
Endpoints 
The main outcome of this study was Non Relapse Mortality (NRM) of allogeneic HCT in 
CR2 comparing patients with prior autologous HCT to patients with chemotherapy 
consolidation. NRM was defined as death without evidence of relapse or progression. CR was 
understood as complete hematologic remission and this was defined as less than 5% bone 
marrow blasts. Relapse was defined as presence of 5% or more bone marrow blasts after 
remission was obtained. 
Secondary outcomes were overall survival (OS) defined as time from allogeneic HCT in CR2 
to death from any cause. LFS was defined as time from allogeneic HCT in CR2 to relapse or 
progression or death from any cause. Acute graft versus host disease (aGVHD) was graded 
according to the modified Seattle-Glucksberg criteria (12) and chronic graft versus host 
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disease (cGVHD) according to the revised Seattle criteria (13). GvHD-free, relapse free 
survival (GFRFS) was defined using the EBMT definition for registry based analyses where 
the time to first event amongst the following is recorded: severe grade III or IV acute GvHD, 
severe chronic GvHD, relapse, death (14).  
Definitions 
Conditioning regimen was defined myeloablative (MAC) when containing total body 
irradiation (TBI) with a dose >6 Gray or a total dose of busulfan (Bu) >8 mg/kg or >6.4 
mg/kg when administered orally or intravenously, respectively. All other regimens were 
defined as RIC (15). Cytogenetic abnormalities were classified according to MRC criteria 
(15). 
Statistics 
Groups were compared using the Mann Whitney U test for continuous and Chi squared test 
for categorical variables. Cumulative incidence was used to estimate the endpoints of NRM, 
relapse incidence (RI), to accommodate for competing risks (17, 18). Probabilities of OS, 
LFS, and GRFS were calculated using the Kaplan–Meier method (19). Univariate analyses 
were done using the Gray’s test for cumulative incidence functions and the log rank test for 
OS, GRFS, and LFS. Continuous variables were entered as continuous covariates in 
multivariate analyses. Cox proportional hazards model were run to adjust for differences 
among groups (20,21) entering all variables differing significantly between the 2 groups. All 
variables differing significantly between the 2 groups or factors known to influence outcomes 
were included in the Cox model: patient age, year of transplant, time to diagnosis to relapse 
and time from relapse to allograft were included as continuous variables. Other variables were 
cytogenetic risk group (favorable, intermediate, adverse or NA), donor type, conditioning 
intensity, sex matching, Karnofsky performance score and patient CMV serology. 
Probabilities of the respective survival times are reported at 2 years after allogeneic HCT. In 
order to test for a centre effect, we introduced a random effect or frailty for each center into 
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the model (22,23). Results were expressed as the hazard ratio (HR) with the 95% confidence 
interval (95%CI). All tests were 2-sided. The type I error rate was fixed at 0.05 for the 
determination of factors associated with time-to-event outcomes. Statistical analyses were 
performed with SPSS 24.0 (SPSS Inc, Chicago, IL, USA) and R 3.4.0 (R Core Team (2017). 
R: A language and environment for statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria. URL  https://www.R-project.org/.)    




This study included: 2619 adults with de novo AML, receiving their first allogeneic HCT in 
CR2 in the years 2000-2017. . Four hundred and seventeen patients had undergone autologous 
HCT as part of the consolidation treatment in CR1 and had subsequently relapsed, 2202 
patients had undergone consolidation treatment by chemotherapy only. Patient, Disease and 
Treatment characteristics are shown in Table 1. Patients with prior autologous HCT differed 
from patients with chemotherapy consolidation in many ways. They were younger by 2.7 
years, were transplanted earlier (median 2009 as compared to 2010), less often had a 
favorable cytogenetic profile, they were more commonly transplanted with alternative donors 
other than matched siblings, and more often had RIC as compared to MAC conditioning. 
Patients with prior autologous HCT had an interval to relapse that was shorter by a median of 
41 days from diagnosis of AML. Time from CR2 to allogeneic HCT was comparable in both 
groups. 
Conditioning for prior autologous HCT was by TBI in 50, by busulphan in combination with 
cyclophosphamide in 168, with melphalan in 56, with other drugs in 34; by drug 
combinations not containing busulphan in 23. The type of conditioning for prior autologous 
HCT was unknown in 86, these had not been reported as transplants to the EBMT. 
 
Univariate outcomes are shown in Table 2 and in Figures 1 (NRM) and 2 (LFS). In univariate 
analysis NRM was higher and LFS lower by approximately 4% in patients with prior 
autologous HCT consolidation as compared to chemotherapy consolidation. Given the 
important differences among groups multivariate analysis adjusting for these differences 
including, patient age, cytogenetic risk, year of transplant, donor type, conditioning intensity, 
sex matching, the time interval from diagnosis to relapse, the time interval from relapse to 
allogeneic HCT into the model are more reliable.  
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Relative Risks of NRM were 1.34 (1.07-1.67), p=0.01 in patients with prior autologous HCT 
vs. chemotherapy consolidation. Similarly LFS risks were 1.17 (1.01-1.35), p=0.03, GRFS 
risks were 1.18 (1.03-1.35) p= 0.02, and OS 1.13 (0.974-1.32), p=0.1 comparing the groups 
with prior autologous HCT to patients with chemotherapy consolidation. A subgroup of 
patients with prior autologous HCT had particularly poor outcome, these were patients who 
had received conditioning by TBI for autologous HCT (n=50) contributing to higher mortality 
of subsequent allogeneic HCT, this had been reported in a previous paper by our group (10). 
Relative risk of NRM was 1.32 (1.03-1.69) for all patients comparing patients with prior 
autologous HCT consolidation to patients without. When analyzing patients with autologous 
HCT conditioned without TBI separately from patients with TBI the risk of NRM of the non-
TBI patients was 1.21 (0.957-1.54) as compared to patients without autologous HCT. 
Conversley, NRM risks of allogeneic HCT were highest in the patients with TBI conditioning 
for autologous HCT (RR: 2.7 (1.67-4.37)). Causes of death after allogeneic HCT in CR2 in 
both groups were dominated by relapsed disease 39.1% and 46.7% and GvHD in 16.4% and 
19.9%, infectious disease with 26.8% vs 19.4% comparing patients with autologous HCT 
consolidation to chemotherapy consolidation in CR1. Sinusoidal obstruction syndrome of the 
liver was the cause of death in 2.7% vs. 1.9% interstitial pneumonitis in 4.1% vs. 2.7%, 
cardiac toxicity in 0.9%vs. 0.7% and secondary malignancy in 3.2% vs. 1.7% of patients, 
respectively. The p value of comparing cause of death was 0.28.  
  




Use of autologous HCT for AML is not well standardized. Some groups advocate this strategy 
as appropriate consolidation treatment in patients with genetically low or intermediate risk 
AML. Use, particularly in CR1 shows a steep increase over the 1990s with a rapid drop after 
the year 2000 as reported to the EBMT activity survey. Authors interpret the data as showing 
a probable switch to allogeneic HCT consolidation at the time when HLA high resolution 
typing became available and large numbers of unrelated donors were accessible for HCT, 
rather than the result of comparative studies, of which only relatively few have been 
published. 
The best evidence for autologous HCT in CR1 comes from a randomized clinical trial 
showing reduced relapse rate by approximately 10% with improved LFS but no significant 
difference in OS (1) published in 2011. This study had not found an interaction between 
relapse risk reduction by autologous HCT and genetic risk categories. Patients in CR1 even if 
in genetic low and intermediate risk categories will have risk of relapse of 40-50% even after 
consolidation by autologous HCT (1). Relapsing patients will most commonly undergo re- 
induction chemotherapy following consolidation in CR2 by allogeneic HCT.  
Previous studies from the ALWP of the EBMT had compared outcome of patients with acute 
leukemia with a relapse after autologous HCT treated with chemotherapy, a second 
autologous HCT or an allogeneic HCT (6, 7). In these studies with patients treated before 
2000, outcome was not significantly different after a second autograft or an allogeneic HCT 
with OS of 42±6% and 32±5%, respectively. Young age and interval from first autograft to 
the second transplant > 8 months and the absence of prior total body irradiation (TBI) had 
more favorable outcome. Outcome of patients treated without a second transplant was very 
poor. A study published in 2013 with 302 patients undergoing an unrelated allogeneic HCT 
for relapse after autologous HCT with either myeloablative (MAC) or reduced-intensity 
conditioning (RIC) showed LFS of 20% at 5 years, results were better in patients with a 
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longer interval to second HCT, a high Karnofsky Performance Score and RIC conditioning 
(8). These studies and the one recently published by the ALWP of the EBMT (10) looked at 
outcome of allogeneic HCT following relapse after autologous HCT report that patients with 
less aggressive disease and in a better state of health fared better. However, these studies did 
not address the issue whether prior autologous HCT impacted the toxicity of subsequent 
allogeneic HCT. 
Here we provide evidence that toxicity measured as NRM is increased after allogeneic HCT 
in CR2 if consolidation in CR1 had been by autologous HCT rather than chemotherapy alone. 
However differences are small i.e. approximately 4% by univariate analysis and it is not clear 
whether this difference is driven by cumulative toxicity of higher doses of chemotherapy or 
by other factors. The groups of patients with prior autologous HCT and chemotherapy 
consolidation differed in many aspects and groups were heterogeneous. In particular, patients 
with prior autologous HCT had more commonly RIC conditioning for allogeneic HCT in 
CR2, in spite of them being younger as compared to the chemotherapy consolidation group. 
As this is an observational study, we do not have control over treatment choices and assume 
that RIC regimens were chosen more commonly in order to avoid toxicity considered to be 
higher, given prior autologous HCT conditioning. Patients with prior autologous HCT had 
more often intermediate risk cytogenetics as compared to chemotherapy consolidation, 
pointing towards a (desired) selection bias. There were however no differences in relapse 
rates. We carefully adjusted for these differences by multivariate analysis in particular also for 
conditioning intensity, but other factors not measured or not appreciated sufficiently may have 
an inpact. For instance, we lack information on the number of chemotherapy cycles to achieve 
CR1 as well as number of cycles to achieve CR2. In addition, there is data missing on the 
conditioning regimen of autologous HCT in a proportion of these patients. Patients with 
conditioning for autologous HCT by TBI fared particularly poorly, but patients without TBI 
conditioning had higher NRM risks, although this was only of borderline significance. Last, 
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this study is obviously agnostic to the benefit of autologous HCT in CR1, i.e. we only 
analyzed patients who experienced a relapse and achieved CR2. We also do not know about 
patients who did not achieve a CR2 or patients who could not undergo an allogeneic HCT in 
CR2 because of lack of donor or comorbid conditions. In spite of these limitations this study 
shows that patients receiving an allograft in CR2 may be at a slightly higher risk of 
nonrelapse mortality after having received a consolidation treatment by autologous HCT as 
compared to chemotherapy consolidation.   
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Figure 1: univariate NRM incidence for patients with prior autologous HCT consolidation vs 
chemotherapy consolidation 
 





























N 2202 417  
Age (IQR) 48.2 (36.9-58.4) 45.5 (36-55.5) 0.003 
Year of transplant 2010 (2006-2014) 2009 (2005-2013) 0.002 
Time to first relapse (d) 406 (281-630) 365 (222-695) 0.03 
         
20 
 
Time relapse to allo HCT (d) 130(15-361)(98-171) 128(29-363)(98-176) NS 
Genetic Risk category   0.001 
  Favorable   569 (29.0% )   55 (18.8% )  
  Intermediate 1244 (63.5% ) 216 (73.7% )  
  Unfavorable   146 (7.5% )   22 (7.5% )  
Karnofsky Performance Score   0.92 
<80 101 (5.1%) 20 (5.2%)  
>=80 1888 (94.9%) 365 (94.8%)  
Patient CMV serology   0.38 
negative 785 (36.3%) 123 (33.9%)  
positive 1380 (63.7%) 240 (66.1%)  
Donor   0.0001 
  Matched sibling   763 (34.7% )   77 (18.5% )  
  Unrelated 1291 (58.6% ) 301 (72.2% )  
  Haploidentical   148 (6.7% )   39 (9.4% )  
Donor recipient sex mismatch   0.22 
  Female into male 401 (18.3% ) 65 (15.7% )  
  Other combinations 1792 (81.7% ) 348 (84.3% )  
Conditioning   0.0001 
  Myeloablative 1227 (55.8% ) 190 (46.1% )  
  Reduced intensity   973 (44.2% ) 222 (53.9% )  
In vivo T-cell depletion   0.08 
  Yes 1252 (57.3% ) 230 (62.2% )  
  No 934 (42.7% ) 140 (37.8% )  
In vitro T-cell depletion 79 (3.6% ) 23 (5.5% ) 0.06 
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Stem cell source   0.11 
  BM 451 (20.5% ) 100 (24.0% )  
  PB 1751 (79.5% ) 317 (76.0% )  
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P MVA* P 
NRM (2y) 21.3%[19.6-23.1] 25.2%[21-29.6] 0.008 1.32 (1.03-1.69) 0.03 
Relapse (2y) 28.1%[26.1-30] 28.6%[24.1-33.2] NS 1.07  (0.85-1.34) 0.58 
OS (2y) 58.1%[55.9-60.2] 55.2%[50.2-60.2] 0.02 1.19 (1.01-1.41) 0.04 
LFS (2y) 50.6%[48.4-52.8] 46.2%[41.2-51.2] 0.004 1.20 (1.02-1.41) 0.03 




25.6% [23.8-27.5] 23.7% [19.6-28] 0.33 0.87 (0.66-1.13) 0.29 
Chronic 
GVHD (2y) 
40.2% [37.9-42.4] 37.5% [32-43] 0.27 0.93 (0.73-1.19) 0.56 
*MVA: Multivariate analysis, Baseline is chemotherapy consolidation with a relative risk of 
event of 1.00; NRM: Non Relapse Mortality, OS: Overall survival, LFS: Leukemia free 
survival; GRFS: GvHD and Leukemia free Survival 
 
         
